Efficacy of BRAF-inhibitor therapy in BRAFV600E -mutated Adult Langerhans Cell Histiocytosis.

Efficacy of BRAF-inhibitor therapy in BRAFV600E -mutated Adult Langerhans Cell Histiocytosis.
Oncologist. 2020 Sep 27;:
Authors: Hazim AZ, Ruan GJ, Ravindran A, Abeykoon JP, Scheckel C, Vassallo R, Ryu JH, Tobin WO, Koster MJ, Bennani NN, Rech KL, Young JR, Shah MV, Goyal G, Go RS
Abstract
Langerhans-cell histiocytosis (LCH) is a rare disease of unknown pathogenesis. To date, there is a lack of FDA-approved treatments in adult LCH to establish optimal first line therapy. We conducted a retrospective, single-center case series evaluating the use of BRAF-inhibitors in adult patients with biopsy proven BRAFV600E - LCH. Our case series is the first to report the use of BRAF-inhibitors as first-line therapy in adults with LCH. We also report the efficacy with single-agent dabrafenib in adult LCH. All but one of our patients had favorable response to targeted therapy.
PMID: 32985015 [PubMed - as supplied by publisher]

Source: The Oncologist - September 26, 2020 Category: Cancer & Oncology Authors: Hazim AZ, Ruan GJ, Ravindran A, Abeykoon JP, Scheckel C, Vassallo R, Ryu JH, Tobin WO, Koster MJ, Bennani NN, Rech KL, Young JR, Shah MV, Goyal G, Go RS Tags: Oncologist Source Type: research